Monthly Archives: February 2019

Top 10 Dividend Stocks To Watch Right Now

Dividend stocks can help income investors sleep at night as the companies often have durable competitive advantages that enable them to increase their dividends often, buy back shares, or both. Two stocks that definitely have competitive advantages and offer a stable dividend are Walmart (NYSE:WMT) and Polaris Industries (NYSE:PII). Sadly, many investors overlook these stocks simply because they screen for dividend yields exceeding 3% — but these two companies are too good to pass up.

E-commerce or bust

Walmart grew its brick-and-mortar business over decades into the juggernaut retailer it is now, but its recent moves have made one thing very clear: It’s e-commerce or bust. Walmart announced on May 9, 2018, that it would acquire a 77% stake in Flipkart, an Indian e-commerce company, for a staggering $16 billion.

It was an expensive move, especially considering Walmart reduced its earnings-per-share guidance for 2018 by $0.25 to $0.30, and it could reduce the retailer’s 2019 earnings by roughly $0.60 per share. While it’s a short-term speed bump for Walmart’s earnings, Morgan Stanley notes that as recently as 2016, only 14% of India’s internet users purchased products online, and that’s expected to jump to 50% as soon as 2026. In addition, India is an attractive geographic region that boasts a rising middle class of consumers.

Top 10 Dividend Stocks To Watch Right Now: Cummins Inc.(CMI)

Advisors’ Opinion:

  • [By Logan Wallace]

    City Holding Co. boosted its position in Cummins Inc. (NYSE:CMI) by 13.6% during the second quarter, HoldingsChannel reports. The institutional investor owned 7,663 shares of the company’s stock after acquiring an additional 920 shares during the quarter. City Holding Co.’s holdings in Cummins were worth $1,019,000 as of its most recent SEC filing.

  • [By Logan Wallace]

    Jacobs & Co. CA increased its stake in shares of Cummins Inc. (NYSE:CMI) by 8.2% in the second quarter, Holdings Channel reports. The firm owned 28,587 shares of the company’s stock after buying an additional 2,175 shares during the period. Jacobs & Co. CA’s holdings in Cummins were worth $3,802,000 as of its most recent SEC filing.

  • [By Max Byerly]

    Cummins (NYSE:CMI) had its target price trimmed by Citigroup from $160.00 to $150.00 in a research report released on Monday. The firm currently has a neutral rating on the stock.

  • [By Ethan Ryder]

    Macquarie Group Ltd. decreased its stake in shares of Cummins Inc. (NYSE:CMI) by 7.9% during the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 18,060 shares of the company’s stock after selling 1,540 shares during the period. Macquarie Group Ltd.’s holdings in Cummins were worth $2,401,000 as of its most recent SEC filing.

  • [By Lee Samaha]

    As you can see in the table above, Resource Industries is currently the smallest segment, but its cyclical recovery is crucial to Caterpillar meeting its guidance. The problem here is that metals and minerals prices have been declining in the last six months, and this calls into question the idea that miners are in the early innings of a long cycle of investment. Throw in talk of near-term weakness from companies like Cummins (NYSE:CMI) — and Caterpillar for that matter — and the outlook is uncertain.

  • [By Maxx Chatsko]

    The near-zero natural gas engines were created by a joint venture between Cummins (NYSE:CMI) and Westport Fuel Systems (NASDAQ:WPRT), called Cummins Westport. Unveiled on May 1, the engine lineup can be used in medium- and heavy-duty trucks, including buses, refuse vehicles, and long-haul trucks. In fact, the ISX 12N engine, as it is called, is the world’s first Class 8 on-highway truck engine to be certified near-zero by the California Air Resources Board, which sets emission standards that are followed by 16 other states. The Tesla Semi and Nikola One are both Class 8 vehicles, or what most people refer to as semis.

Top 10 Dividend Stocks To Watch Right Now: America First Tax Exempt Investors L.P.(ATAX)

Advisors’ Opinion:

  • [By Shane Hupp]

    Shares of America First Tax Exempt Investors, L.P. (NASDAQ:ATAX) hit a new 52-week high and low during mid-day trading on Monday . The company traded as low as $6.47 and last traded at $6.43, with a volume of 54800 shares changing hands. The stock had previously closed at $6.43.

  • [By Joseph Griffin]

    Bank of Montreal Can bought a new position in shares of America First Multifamily Investors LP (NASDAQ:ATAX) during the 2nd quarter, according to its most recent Form 13F filing with the SEC. The institutional investor bought 22,500 shares of the financial services provider’s stock, valued at approximately $143,000.

  • [By Stephan Byrd]

    BidaskClub upgraded shares of America First Multifamily Investors (NASDAQ:ATAX) from a strong sell rating to a sell rating in a research report sent to investors on Thursday morning.

  • [By Joseph Griffin]

    America First Multifamily Investors LP (NASDAQ:ATAX) announced a quarterly dividend on Friday, September 14th, Wall Street Journal reports. Stockholders of record on Friday, September 28th will be given a dividend of 0.125 per share by the financial services provider on Wednesday, October 31st. This represents a $0.50 annualized dividend and a dividend yield of 8.50%. The ex-dividend date is Thursday, September 27th.

  • [By Max Byerly]

    Get a free copy of the Zacks research report on America First Multifamily Investors (ATAX)

    For more information about research offerings from Zacks Investment Research, visit Zacks.com

  • [By Motley Fool Transcribers]

    America First Multifamily Investors LP (NASDAQ:ATAX)Q2 2018 Earnings Conference CallAug. 13, 2018, 4:30 p.m. ET

    Contents:
    Prepared Remarks Questions and Answers Call Participants
    Prepared Remarks:

    Operator

Top 10 Dividend Stocks To Watch Right Now: Littelfuse Inc.(LFUS)

Advisors’ Opinion:

  • [By Logan Wallace]

    Get a free copy of the Zacks research report on Littelfuse (LFUS)

    For more information about research offerings from Zacks Investment Research, visit Zacks.com

  • [By Ethan Ryder]

    Littelfuse, Inc. (NASDAQ:LFUS) SVP Matthew Cole sold 150 shares of the business’s stock in a transaction dated Wednesday, August 8th. The shares were sold at an average price of $227.26, for a total transaction of $34,089.00. Following the transaction, the senior vice president now directly owns 4,163 shares of the company’s stock, valued at $946,083.38. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website.

  • [By Joseph Griffin]

    Get a free copy of the Zacks research report on Littelfuse (LFUS)

    For more information about research offerings from Zacks Investment Research, visit Zacks.com

  • [By Shane Hupp]

    Teacher Retirement System of Texas reduced its holdings in Littelfuse, Inc. (NASDAQ:LFUS) by 7.9% during the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 5,036 shares of the technology company’s stock after selling 430 shares during the period. Teacher Retirement System of Texas’ holdings in Littelfuse were worth $1,149,000 as of its most recent SEC filing.

  • [By Joseph Griffin]

    SG Americas Securities LLC raised its position in Littelfuse, Inc. (NASDAQ:LFUS) by 72.3% in the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 4,391 shares of the technology company’s stock after purchasing an additional 1,843 shares during the period. SG Americas Securities LLC’s holdings in Littelfuse were worth $914,000 at the end of the most recent reporting period.

  • [By Ethan Ryder]

    Littelfuse (NASDAQ:LFUS) was upgraded by stock analysts at ValuEngine from a “hold” rating to a “buy” rating in a report issued on Thursday.

Top 10 Dividend Stocks To Watch Right Now: S&P GSCI(GD)

Advisors’ Opinion:

  • [By Stephan Byrd]

    Summit Financial Group Inc. lowered its position in General Dynamics Co. (NYSE:GD) by 26.8% in the second quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 5,470 shares of the aerospace company’s stock after selling 2,000 shares during the quarter. Summit Financial Group Inc.’s holdings in General Dynamics were worth $1,020,000 as of its most recent SEC filing.

  • [By Lou Whiteman]

    Scale matters in the government IT business, as larger companies are better able to manage the increasingly large and complex systems customers demand, and a broader cost basis helps in putting together low-cost, competitive bids. In recent years, a wave of mergers and acquisitions has left a clear top two in the market. Industry leader Leidos Holdings (NYSE:LDOS) in 2016 bought the IT business of Lockheed Martin, while General Dynamics (NYSE:GD) vaulted to No. 2 earlier this year via its acquisition of CSRA.

  • [By ]

    Finally, General Dynamics Corp. (GD) , along with Lockheed and BAE Systems, could possibly profit from heightened demand ships and other vehicles. 

Top 10 Dividend Stocks To Watch Right Now: UniSource Energy Corporation(UNS)

Advisors’ Opinion:

  • [By Max Byerly]

    Uni Select (TSE:UNS)‘s stock had its “hold” rating restated by equities research analysts at TD Securities in a report issued on Friday. They currently have a C$24.00 price objective on the stock. TD Securities’ price target points to a potential upside of 8.21% from the stock’s current price.

  • [By Ethan Ryder]

    Uni Select (TSE:UNS) had its price target lifted by investment analysts at Macquarie from C$24.00 to C$25.00 in a report released on Wednesday. Macquarie’s price objective suggests a potential upside of 18.32% from the stock’s current price.

Top 10 Dividend Stocks To Watch Right Now: Laboratory Corporation of America Holdings(LH)

Advisors’ Opinion:

  • [By Joseph Griffin]

    Envestnet Asset Management Inc. reduced its position in shares of LabCorp (NYSE:LH) by 45.1% during the first quarter, HoldingsChannel.com reports. The fund owned 19,179 shares of the medical research company’s stock after selling 15,727 shares during the quarter. Envestnet Asset Management Inc.’s holdings in LabCorp were worth $3,116,000 at the end of the most recent reporting period.

  • [By Shane Hupp]

    These are some of the headlines that may have impacted Accern’s analysis:

    Get LabCorp alerts:

    $2.92 Earnings Per Share Expected for LabCorp (LH) This Quarter (americanbankingnews.com) Global Contract Research Organization Market 2018 Pioneers by 2023: Parexel, LabCorp (Covance), PRA, PPD … (theexpertconsulting.com) OmniSeq and LabCorp Launch OmniSeq Advance? Assay (nasdaq.com) LabCorp’s latest collaboration aims to accelerate personalized, genomic medicine (bizjournals.com) Can Laboratory Corporation of America Holdings (NYSE:LH) Continue To Outperform Its Industry? (finance.yahoo.com)

    LH has been the topic of several analyst reports. Barclays lifted their target price on shares of LabCorp from $195.00 to $210.00 and gave the stock an “overweight” rating in a research note on Monday, February 26th. They noted that the move was a valuation call. Zacks Investment Research raised shares of LabCorp from a “hold” rating to a “buy” rating and set a $190.00 target price on the stock in a research note on Friday, February 9th. Jefferies Group reaffirmed a “hold” rating and issued a $176.00 target price on shares of LabCorp in a research note on Tuesday, March 6th. ValuEngine raised shares of LabCorp from a “hold” rating to a “buy” rating in a research note on Friday, February 2nd. Finally, Morgan Stanley lifted their target price on shares of LabCorp from $182.00 to $192.00 and gave the stock an “overweight” rating in a research note on Wednesday, February 28th. Five research analysts have rated the stock with a hold rating, twelve have given a buy rating and two have assigned a strong buy rating to the stock. LabCorp has an average rating of “Buy” and an average target price of $191.06.

  • [By Joseph Griffin]

    Renaissance Technologies LLC trimmed its position in Laboratory Corp. of America Holdings (NYSE:LH) by 39.0% during the second quarter, according to its most recent 13F filing with the SEC. The fund owned 556,105 shares of the medical research company’s stock after selling 355,300 shares during the period. Renaissance Technologies LLC owned about 0.55% of Laboratory Corp. of America worth $99,838,000 as of its most recent filing with the SEC.

  • [By Joseph Griffin]

    Here are some of the headlines that may have impacted Accern Sentiment’s rankings:

    Get Laboratory Corp. of America alerts:

    Stock Traders Buy Large Volume of Laboratory Corp. of America Put Options (LH) (americanbankingnews.com) Credit Suisse Group Lowers Laboratory Corp. of America (LH) to Hold (americanbankingnews.com) Laboratory Corp. of America (LH) Set to Announce Quarterly Earnings on Wednesday (americanbankingnews.com) Can LaunchPad Aid LabCorp's (LH) Covance Arm in Q1 Earnings? (finance.yahoo.com) As Laboratory Corp Of America Holdings (LH) Shares Rose, Shareholder Veritas Investment Management Llp … (djzplanet.com)

    LH has been the subject of several research analyst reports. Craig Hallum restated a “buy” rating and set a $204.00 price target (up from $180.00) on shares of Laboratory Corp. of America in a research note on Wednesday, February 7th. Morgan Stanley upped their target price on Laboratory Corp. of America from $182.00 to $192.00 and gave the stock an “overweight” rating in a research report on Wednesday, February 28th. Zacks Investment Research downgraded Laboratory Corp. of America from a “hold” rating to a “sell” rating in a research report on Wednesday, January 3rd. Mizuho set a $178.00 target price on Laboratory Corp. of America and gave the stock a “hold” rating in a research report on Wednesday, January 24th. Finally, Robert W. Baird set a $183.00 target price on Laboratory Corp. of America and gave the stock a “hold” rating in a research report on Thursday, February 8th. Seven investment analysts have rated the stock with a hold rating, ten have assigned a buy rating and two have assigned a strong buy rating to the company. The company presently has an average rating of “Buy” and a consensus price target of $189.19.

  • [By Motley Fool Transcribers]

    Laboratory Corp Of America Holdings  (NYSE:LH)Q4 2018 Earnings Conference CallFeb. 07, 2019, 9:00 a.m. ET

    Contents:
    Prepared Remarks Questions and Answers Call Participants
    Prepared Remarks:

    Operator

  • [By Shane Hupp]

    Laboratory Corp. of America (NYSE: LH) and OpGen (NASDAQ:OPGN) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their earnings, analyst recommendations, profitability, risk, valuation, institutional ownership and dividends.

Top 10 Dividend Stocks To Watch Right Now: Cellcom Israel Ltd.(CEL)

Advisors’ Opinion:

  • [By Ethan Ryder]

    Millicom (OTCMKTS: MIICF) and Cellcom Israel (NYSE:CEL) are both computer and technology companies, but which is the better business? We will contrast the two businesses based on the strength of their risk, valuation, dividends, institutional ownership, analyst recommendations, earnings and profitability.

  • [By Lisa Levin]

    Thursday afternoon, the health care shares rose 1.79 percent. Meanwhile, top gainers in the sector included Partner Communications Company Ltd. (NASDAQ: PTNR), up 8 percent, and Cellcom Israel Ltd. (NYSE: CEL) up 7 percent.

  • [By Lisa Levin]

    Thursday afternoon, the telecommunication services shares surged 0.58 percent. Meanwhile, top gainers in the sector included Intelsat S.A. (NYSE: I), up 5 percent, and Cellcom Israel Ltd. (NYSE: CEL) up 2.5 percent.

  • [By Stephan Byrd]

    Partner Communications (NASDAQ: PTNR) and Cellcom Israel (NYSE:CEL) are both small-cap computer and technology companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, analyst recommendations, institutional ownership, risk, valuation, profitability and dividends.

  • [By Ethan Ryder]

    Hellenic Telecom Organization (NYSE: CEL) and Cellcom Israel (NYSE:CEL) are both utilities companies, but which is the better investment? We will contrast the two businesses based on the strength of their profitability, earnings, valuation, risk, institutional ownership, dividends and analyst recommendations.

Top 10 Dividend Stocks To Watch Right Now: Amphenol Corporation(APH)

Advisors’ Opinion:

  • [By Max Byerly]

    WESPAC Advisors SoCal LLC reduced its position in shares of Amphenol Co. (NYSE:APH) by 3.1% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 7,725 shares of the electronics maker’s stock after selling 250 shares during the period. WESPAC Advisors SoCal LLC’s holdings in Amphenol were worth $626,000 at the end of the most recent reporting period.

  • [By Ethan Ryder]

    Greenleaf Trust reduced its holdings in Amphenol (NYSE:APH) by 4.0% during the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 17,234 shares of the electronics maker’s stock after selling 714 shares during the period. Greenleaf Trust’s holdings in Amphenol were worth $1,484,000 as of its most recent SEC filing.

  • [By Tom Gentile]

    The Amephenol Corp. (NYSE: APH) is an electronic and fiber optic manufacturing company in Connecticut. Late last month, on April 25, the company released their earnings and beat all expectations, including earnings per share and reported revenue.

  • [By Joseph Griffin]

    Aphria Inc (TSE:APH)’s share price shot up 14% during trading on Wednesday . The stock traded as high as C$20.36 and last traded at C$19.86. 16,904,801 shares changed hands during trading, an increase of 184% from the average session volume of 5,950,322 shares. The stock had previously closed at C$17.42.

  • [By Logan Wallace]

    Get a free copy of the Zacks research report on Amphenol (APH)

    For more information about research offerings from Zacks Investment Research, visit Zacks.com

Top 10 Dividend Stocks To Watch Right Now: Lorillard Inc(LO)

Advisors’ Opinion:

  • [By Shane Hupp]

    News articles about Lorillard (NYSE:LO) have been trending extremely positive recently, according to Accern Sentiment. Accern identifies negative and positive media coverage by analyzing more than twenty million news and blog sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores nearest to one being the most favorable. Lorillard earned a news impact score of 0.81 on Accern’s scale. Accern also gave news coverage about the company an impact score of 44.1727475800447 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the stock’s share price in the next several days.

Top 10 Dividend Stocks To Watch Right Now: Tyco International Ltd.(Switzerland)

Advisors’ Opinion:

  • [By ]

    In addition to South Korea’s small ETF, there are a few funds traded in Europe that track Mexican assets. Here are the ones to watch:

    Xtrackers MSCI Mexico UCITS ETF (Germany)iShares MSCI Mexico Capped UCITS ETF USD (Switzerland)HSBC MSCI Mexico Capped UCITS ETF (U.K.)Kim Kindex MSCI Mexico ETF (South Korea)Stocks

    Some of the larger companies based in Mexico are dual listed in Europe. While trading in these securities is limited, there may be some movement in the European morning hours. Here are a few to watch:

Why Axon Enterprise, Mylan, and Weight Watchers International Slumped Today

The stock market spent most of the session in the red on Wednesday, but by the close, that was far from evident. The Dow Jones Industrial Average fell about 70 points, but other major indexes finished closer to unchanged as investors took solace in the continued strength of the U.S. economy. Even with that tailwind, some individual companies weren’t so fortunate, suffering from business-specific challenges that hurt their share prices. Axon Enterprise (NASDAQ:AAXN), Mylan (NASDAQ:MYL), and Weight Watchers International (NASDAQ:WTW) were among the worst performers. Here’s why they did so poorly.

Axon gets zapped

Shares of Axon Enterprise fell 8% after the Taser maker reported its fourth-quarter financial results. Axon saw a 21% rise in revenue, led higher by big gains in its cloud business and in sales from international sources. Bookings for its software and sensor offerings climbed by more than half as well, and other backward-looking metrics looked strong. However, top-line gains didn’t translate into as much earnings growth as investors had wanted to see, and shareholders also seemed put off by guidance for 2019, which includes sales projections for growth of just 14% to 17%. Axon will just have to prove that it can sustain faster growth if it wants to regain investors’ confidence.

Police officer with Axon branded body camera prominently displayed on upper torso.

Image source: Axon Enterprise.

Mylan doesn’t look well

Mylan saw its stock drop 15% following the release of the pharmaceutical giant’s fourth-quarter report. Revenue for the quarter was down 5% from the year-ago period, and adjusted earnings fell 9% on a per-share basis, closing a tough year for the company. Moreover, continuing manufacturing challenges at its West Virginia facility plagued Mylan, and even though the drugmaker hopes that 2019 will prove more promising, anticipated sales growth won’t necessarily translate into higher profit. In the long run, Mylan will have to show that investments in its research and development capabilities will pay off with blockbuster drugs.

Weight Watchers leaves investors confused

Finally, shares of Weight Watchers International plunged over 34%. The weight loss and wellness specialist reported a 6% rise in revenue in the fourth quarter of 2018, with adjusted operating income climbing 28%. But guidance for 2019 was extremely weak, with calls for $1.25 to $1.50 in earnings per share comparing terribly to the $3.19 per share that Weight Watchers posted in 2018. Early reads on the key January membership season also showed poor results, and the company’s name change to WW was badly communicated and confusing to customers. CEO Mindy Grossman still believes that changing the company’s emphasis from weight loss to wellness fits better with shifting consumer preferences, but with heavy competition in the industry, Weight Watchers can’t afford any further missteps in execution.

Exxon Mobil Co. (XOM) Stake Lessened by Cadinha & Co. LLC

Cadinha & Co. LLC lessened its stake in shares of Exxon Mobil Co. (NYSE:XOM) by 22.0% during the third quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 27,472 shares of the oil and gas company’s stock after selling 7,750 shares during the quarter. Cadinha & Co. LLC’s holdings in Exxon Mobil were worth $2,336,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Swiss National Bank raised its position in shares of Exxon Mobil by 2.9% during the second quarter. Swiss National Bank now owns 15,058,036 shares of the oil and gas company’s stock valued at $1,245,751,000 after buying an additional 423,200 shares during the last quarter. Sumitomo Mitsui Trust Holdings Inc. raised its position in shares of Exxon Mobil by 8.2% during the second quarter. Sumitomo Mitsui Trust Holdings Inc. now owns 13,735,708 shares of the oil and gas company’s stock valued at $1,136,355,000 after buying an additional 1,045,871 shares during the last quarter. LSV Asset Management raised its position in shares of Exxon Mobil by 5.1% during the second quarter. LSV Asset Management now owns 9,895,042 shares of the oil and gas company’s stock valued at $818,616,000 after buying an additional 477,971 shares during the last quarter. Fisher Asset Management LLC raised its position in shares of Exxon Mobil by 4.1% during the third quarter. Fisher Asset Management LLC now owns 5,855,133 shares of the oil and gas company’s stock valued at $497,803,000 after buying an additional 228,513 shares during the last quarter. Finally, Bank of Montreal Can raised its position in shares of Exxon Mobil by 36.4% during the third quarter. Bank of Montreal Can now owns 5,317,473 shares of the oil and gas company’s stock valued at $452,092,000 after buying an additional 1,420,065 shares during the last quarter. 53.20% of the stock is currently owned by hedge funds and other institutional investors.

Get Exxon Mobil alerts:

Shares of XOM opened at $79.47 on Thursday. Exxon Mobil Co. has a fifty-two week low of $64.65 and a fifty-two week high of $87.36. The firm has a market capitalization of $332.30 billion, a P/E ratio of 16.12, a price-to-earnings-growth ratio of 1.75 and a beta of 0.90. The company has a current ratio of 0.83, a quick ratio of 0.54 and a debt-to-equity ratio of 0.10.

Exxon Mobil (NYSE:XOM) last posted its quarterly earnings data on Friday, February 1st. The oil and gas company reported $1.51 earnings per share for the quarter, beating the Zacks’ consensus estimate of $1.08 by $0.43. Exxon Mobil had a net margin of 7.18% and a return on equity of 10.89%. The business had revenue of $71.90 billion for the quarter, compared to analysts’ expectations of $78.87 billion. During the same quarter in the previous year, the business posted $0.88 earnings per share. The business’s revenue was up 8.1% compared to the same quarter last year. As a group, analysts anticipate that Exxon Mobil Co. will post 4.09 EPS for the current year.

The company also recently disclosed a quarterly dividend, which will be paid on Monday, March 11th. Shareholders of record on Monday, February 11th will be given a dividend of $0.82 per share. This represents a $3.28 dividend on an annualized basis and a yield of 4.13%. The ex-dividend date of this dividend is Friday, February 8th. Exxon Mobil’s dividend payout ratio (DPR) is 66.53%.

In other Exxon Mobil news, VP David S. Rosenthal sold 7,562 shares of the business’s stock in a transaction on Tuesday, December 4th. The shares were sold at an average price of $81.24, for a total transaction of $614,336.88. Following the transaction, the vice president now owns 258,250 shares in the company, valued at $20,980,230. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, VP Robert N. Schleckser sold 7,855 shares of the business’s stock in a transaction on Friday, November 30th. The shares were sold at an average price of $78.91, for a total transaction of $619,838.05. Following the transaction, the vice president now owns 207,940 shares in the company, valued at approximately $16,408,545.40. The disclosure for this sale can be found here. Insiders have sold 58,587 shares of company stock worth $4,507,808 in the last quarter. Company insiders own 0.08% of the company’s stock.

Several equities research analysts have recently issued reports on XOM shares. HSBC reiterated a “buy” rating and set a $95.00 price objective on shares of Exxon Mobil in a research report on Tuesday, November 6th. Societe Generale set a $92.00 price target on shares of Exxon Mobil and gave the stock a “buy” rating in a research report on Tuesday, November 20th. Royal Bank of Canada set a $95.00 price target on shares of Exxon Mobil and gave the stock a “buy” rating in a research report on Friday, February 1st. Argus restated a “buy” rating on shares of Exxon Mobil in a research report on Wednesday, February 6th. Finally, Mizuho set a $77.00 price target on shares of Exxon Mobil and gave the stock a “hold” rating in a research report on Wednesday, November 28th. Three research analysts have rated the stock with a sell rating, twelve have given a hold rating and nine have issued a buy rating to the company’s stock. The company has a consensus rating of “Hold” and an average price target of $84.57.

COPYRIGHT VIOLATION NOTICE: This piece was posted by Ticker Report and is owned by of Ticker Report. If you are reading this piece on another website, it was stolen and republished in violation of United States & international copyright legislation. The legal version of this piece can be accessed at www.tickerreport.com/banking-finance/4184839/exxon-mobil-co-xom-stake-lessened-by-cadinha-co-llc.html.

About Exxon Mobil

Exxon Mobil Corporation explores for and produces crude oil and natural gas in the United States, Canada/Other Americas, Europe, Africa, Asia, and Australia/Oceania. It operates through Upstream, Downstream, and Chemical segments. The company also manufactures petroleum products; manufactures and markets commodity petrochemicals, including olefins, aromatics, polyethylene, and polypropylene plastics, as well as various specialty products; produces transportation fuels, such as marine gasoil and diesel; and transports and sells crude oil, natural gas, and petroleum products.

Recommended Story: Outstanding Shares

Want to see what other hedge funds are holding XOM? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Exxon Mobil Co. (NYSE:XOM).

Institutional Ownership by Quarter for Exxon Mobil (NYSE:XOM)

Hot Low Price Stocks To Own Right Now

Source: ThinkstockUntil about 2008 or so, discussion about the future price of crude oil was directed by the concept of peak oil. That is, when does the world reach peak production, after which the price of crude will skyrocket. In less than a decade, the discussion is now focused on the concept of “peak demand,” the point at which global demand for crude begins to decline.

The recent Oil & Money conference in London sharpened the focus on peak demand. Saudi Arabia’s minister of energy and industry, Khalid Al-Falih, told conference attendees that cutbacks in capital spending on exploration, forced on the industry by low prices for the past two years, could mean that shortfalls in supply are coming.

Exxon Mobil Corp. (NYSE: XOM) CEO Rex Tillerson disagreed:

Hot Low Price Stocks To Own Right Now: Aceto Corporation(ACET)

Advisors’ Opinion:

  • [By Joseph Griffin]

    Aceto (NASDAQ: ACET) and PetIQ (NASDAQ:PETQ) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their risk, analyst recommendations, earnings, institutional ownership, valuation, dividends and profitability.

  • [By Shane Hupp]

    Aceto (NASDAQ: ACET) and PetIQ (NASDAQ:PETQ) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, dividends, earnings, valuation, risk, analyst recommendations and institutional ownership.

  • [By Chris Lange]

    Aceto Corp. (NASDAQ: ACET) saw its shares halved on Thursday after the company gave a critical update. There is a lot going on for Aceto in this update, and most of it is not good news. Amid credit negotiations there are also changes at the highest level of management, making this a tough pill to swallow.

  • [By Stephan Byrd]

    Aceto (NASDAQ:ACET) will be posting its quarterly earnings results after the market closes on Wednesday, September 12th. Analysts expect Aceto to post earnings of $0.26 per share for the quarter.

  • [By Lisa Levin]

    Check out these big penny stock gainers and losers

    Losers
    Prothena Corporation plc (NASDAQ: PRTA) shares dipped 69 percent to $11.48 after a disappointing update relating to the company's treatment for AL amyloidosis. Prothena, a clinical-stage biopharmaceutical company that focuses on therapies in the neuroscience and orphan categories, said a Phase 2b study of its therapy called NEOD001 failed to achieve its primary or secondary endpoints. Prothena's Phase 2b study explored its NEOD001 therapy versus a placebo in previously-treated patients with AL amyloidosis and persistent cardiac dysfunction.
    Gridsum Holding Inc. (NASDAQ: GSUM) fell 44.3 percent to $4.06. Gridsum reported suspension of audit report on financial statements.
    Flotek Industries, Inc. (NYSE: FTK) shares declined 34.1 percent to $4.16 as the company issued weak revenue forecast for the first quarter.
    Akorn, Inc. (NASDAQ: AKRX) dropped 32.3 percent to $13.35 after Fresenius terminated its merger deal with Akorn.
    Chicago Bridge & Iron Company N.V. (NYSE: CBI) fell 31.2 percent to $13.44. Subsea 7 made an unsolicited bid to buy McDermott for $7 per share. However, the acquisition offer is contingent on McDermot terminating its pending merger with Chicago Bridge & Iron.
    Controladora Vuela Compañía de Aviación, S.A.B. de C.V. (NYSE: VLRS) dropped 18 percent to $5.76. Controladora Vuela recently reported first-quarter results that showed a loss for the quarter. Imperial Capital downgraded Controladora Vuela Compania de Aviacion from Outperform to In-Line.
    Atossa Genetics Inc. (NASDAQ: ATOS) fell 18.2 percent to $2.8797 after declining 19.35 percent on Friday.
    Alcoa Corporation (NYSE: AA) fell 12.3 percent to $52.63.
    Luby's, Inc. (NYSE: LUB) shares declined 10.3 percent to $2.448 following Q2 results.
    Aceto Corporation (NASDAQ: ACET) shares tumbled 10 percent to $2.26.
    Pier 1 Imports, Inc. (NYSE: PIR) dipped 9.7 percent

  • [By Lisa Levin]

    Aceto Corporation (NYSE: ACET) shares dropped 62 percent to $2.795 following announcement of financial challenges. The company has suspended further guidance and is evaluating strategic alternatives. Aceto also expects reduction in dividend moving forward. Canaccord Genuity downgraded Aceto from Buy to Sell.

Hot Low Price Stocks To Own Right Now: Capital Senior Living Corporation(CSU)

Advisors’ Opinion:

  • [By Logan Wallace]

    Barclays reissued their average rating on shares of Capital Senior Living (NYSE:CSU) in a research note released on Monday morning.

    Several other equities analysts have also issued reports on the company. ValuEngine lowered Capital Senior Living from a strong-buy rating to a buy rating in a research note on Thursday, December 27th. JMP Securities restated an outperform rating on shares of Capital Senior Living in a research note on Monday, December 31st. Finally, Zacks Investment Research upgraded Capital Senior Living from a hold rating to a buy rating and set a $8.75 price target on the stock in a research note on Monday, January 21st. Four research analysts have rated the stock with a hold rating and two have issued a buy rating to the stock. Capital Senior Living presently has a consensus rating of Hold and an average price target of $9.38.

  • [By Max Byerly]

    State of New Jersey Common Pension Fund D lessened its stake in shares of Capital Senior Living (NYSE:CSU) by 5.3% in the first quarter, Holdings Channel reports. The institutional investor owned 180,000 shares of the company’s stock after selling 10,000 shares during the quarter. State of New Jersey Common Pension Fund D’s holdings in Capital Senior Living were worth $1,935,000 as of its most recent filing with the SEC.

  • [By Joseph Griffin]

    Get a free copy of the Zacks research report on Capital Senior Living (CSU)

    For more information about research offerings from Zacks Investment Research, visit Zacks.com

  • [By Stephan Byrd]

    Media stories about Capital Senior Living (NYSE:CSU) have trended somewhat positive on Sunday, Accern Sentiment Analysis reports. The research firm rates the sentiment of press coverage by reviewing more than 20 million blog and news sources in real-time. Accern ranks coverage of companies on a scale of negative one to one, with scores nearest to one being the most favorable. Capital Senior Living earned a daily sentiment score of 0.01 on Accern’s scale. Accern also assigned press coverage about the company an impact score of 46.062391046142 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the stock’s share price in the immediate future.

Hot Low Price Stocks To Own Right Now: Applied DNA Sciences Inc(APDN)

Advisors’ Opinion:

  • [By Logan Wallace]

    Media coverage about Applied DNA Sciences (NASDAQ:APDN) has trended somewhat positive on Monday, Accern Sentiment Analysis reports. The research firm rates the sentiment of press coverage by analyzing more than 20 million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores closest to one being the most favorable. Applied DNA Sciences earned a daily sentiment score of 0.04 on Accern’s scale. Accern also assigned press coverage about the technology company an impact score of 47.7961768116482 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the stock’s share price in the next several days.

  • [By Stephan Byrd]

    Applied DNA Sciences Inc (NASDAQ:APDN) shares rose 5.3% during mid-day trading on Wednesday . The company traded as high as $1.84 and last traded at $1.60. Approximately 2,707 shares were traded during mid-day trading, a decline of 98% from the average daily volume of 165,954 shares. The stock had previously closed at $1.52.

  • [By Shane Hupp]

    Ascent Capital Group (NASDAQ: ASCMA) and Applied DNA Sciences (NASDAQ:APDN) are both small-cap industrial products companies, but which is the superior stock? We will contrast the two businesses based on the strength of their analyst recommendations, valuation, dividends, risk, profitability, earnings and institutional ownership.

Hot Low Price Stocks To Own Right Now: Morgan Stanley Asia-Pacific Fund, Inc.(APF)

Advisors’ Opinion:

  • [By Stephan Byrd]

    Peel Hunt upgraded shares of Anglo Pacific Group (LON:APF) to a buy rating in a report released on Tuesday morning. Peel Hunt currently has GBX 190 ($2.53) target price on the stock, up from their previous target price of GBX 181 ($2.41).

Is Marijuana Stock GW Pharmaceuticals a Buy Following Its Quarterly Results?

GW Pharmaceuticals (NASDAQ:GWPH) has the distinction of being the only company to secure Food and Drug Administration (FDA) approval for a cannabidiol (CBD) marijuana therapy. The company’s Epidiolex won the FDA green light last summer after demonstrating it reduces seizures in epilepsy patients. GW Pharmaceuticals launched Epidiolex in November after it received the most favorable Drug Enforcement Agency scheduling possible. On Tuesday, management unveiled results, including Epidiolex’s initial commercial performance. Is this pot stock a buy?

What it does

Epidiolex is a purified CBD that’s secured regulatory approval for use in patients with Dravet syndrome and Lennox-Gastaut syndrome (LGS), two tough-to-treat forms of epilepsy. Patients with Dravet syndrome or LGS often don’t respond to existing antiepileptic therapies, making new treatment options like Epidiolex particularly important.

Marijuana growing at a GW Pharmaceuticals greenhouse.

IMAGE SOURCE: GW Pharmaceuticals.

In trials involving patients who had tried and failed on existing antiepileptic medications, using Epidiolex reduced seizure frequency from between 40% and 50%.

The commercial opportunity is big

The addressable market of Dravet and LGS patients is relatively small at about 35,000. However, Epidiolex costs $32,500, and many more patients suffering from resistant forms of epilepsy could someday benefit from its use.

There are about 3.4 million Americans with epilepsy, 470,000 of whom are children, and approximately one-third of those patients are inadequately treated by traditional antiepileptic medications.

The need for new treatment alternatives for patients has helped GW Pharmaceuticals overcome payer objections. In January, the company said 22 million people covered by Express Scripts drug formulary could access Epidiolex without prior authorization and that four of the five biggest commercial insurers have initiated coverage of Epidiolex after prior authorization.

How’d it do?

On Feb. 26, GW Pharmaceuticals unveiled results for the quarter ending Dec. 31. In the period, the focus was on educating doctors about Epidiolex’s risks and benefits, yet sales still clocked in at $4.7 million.

That’s not a lot, but sales could grow meaningfully in 2019. About 4,500 patient enrollment forms were filled out in the drug’s first two months, and over 500 doctors have already written a prescription. In January, filled prescriptions grew 150% from December 2018.

A man looks through binoculars.

IMAGE SOURCE: GETTY IMAGES.

What to watch next

Prescription renewal rates and new prescription trends will be key to track in 2019. If patients are refilling and doctors demonstrate their confidence by writing increasingly more scripts, then it would add credence to the thinking that Epidiolex can generate sales in the nine figures or higher someday.

Investors will also want to watch for phase 3 data from a trial evaluating Epidiolex in tuberous sclerosis complex (TSC). Epilepsy is the most common symptom of TSC, and there are about 25,000 TSC patients who could benefit from Epidiolex if its trial pans out. Results from this study are anticipated in the second quarter. If successful, a filing for approval in TSC is planned before the end of 2019.

Epidiolex’s commercial opportunity could expand sooner than that, though. The European Union is expected to weigh in with a go/no-go decision on Epidiolex in the coming months. If approved, management hopes to launch it in France, Germany, Italy, Spain, and the U.K. this year.

Overall, Epidiolex is off to a solid start, but a lot still needs to happen for GW Pharmaceuticals to transition into a profitable drugmaker. At $80 million, the company’s operating expenses far outstripped its revenue, resulting in a net loss of $72 million last quarter. Therefore, only aggressive investors who can withstand the risk of ongoing losses ought to consider adding this company to their portfolio following these results.